Objectives: Antiseizure drugs are the leading therapeutic choice for treatment of epilepsy, but their efficacy is limited by pharmacoresistance and the occurrence of unwanted side effects. Here, we examined the therapeutic efficacy of KCNQ channel activation by retigabine in preventing seizures and neurocardiac dysfunction in 2 potassium channelopathy mouse models of epilepsy with differing severity that have been associated with increased risk of sudden unexpected death in epilepsy (SUDEP): the Kcna1 À/À model of severe epilepsy and the Kcnq1 A340E/A340E model of mild epilepsy.
| INTRODUCTION
Studies in mouse models suggest that activation of voltagegated KCNQ (Kv7) potassium channels could be an effective pharmacologic approach to prevent aberrant neurocardiac activity and thereby decrease risk for sudden unexpected death in epilepsy (SUDEP) risk. In ex vivo experiments using Kcna1 knockout (Kcna1 À/À ) mice, a well-characterized model of SUDEP involving brain-heart dysregulation via the parasympathetic nervous system, Kcna1 À/À vagal axons exhibit abnormal spontaneous firing that is almost completely abolished by augmenting Kv7 currents with the KCNQ channel opener flupirtine. 1 In Sentrin/small ubiquitin-like modifier (SUMO)-specific protease 2 deficient mice, which exhibit seizures and sudden death as a result of hyper-SUMOylation of multiple potassium channels, in vivo treatment with retigabine (RTG), a more potent analog of flupirtine, prevents acoustically induced seizures and vagally mediated, seizure-associated atrioventricular (AV) blocks. 2 Thus KCNQ openers show promise for preventing SUDEP in cases involving neurocardiac or parasympathetic mechanisms, since they can not only suppress seizures, but also potentially help maintain normal vagal activity. Here, we explored the potential of KCNQ channel activation as a pharmacologic strategy to prevent seizures and neurocardiac dysfunction in 2 potassium channelopathy mouse models of epilepsy of differing severity that have been associated with sudden death: the Kcna1 À/À model of severe epilepsy and the Kcnq1 A340E/A340E model of mild epilepsy. Kcna1 À/À mice lack Kv1.1 voltage-gated potassium channel a-subunits and exhibit several key features of human SUDEP including severe early onset epilepsy characterized by frequent generalized tonic-clonic seizures (up to~24/d); premature sudden death beginning at a young age (~P16); and seizure-evoked bradyarrhythmias that progress to cardiac arrest. [3] [4] [5] [6] Kv1.1 channel mutations have been identified as a molecular cause of epilepsy in patients and a de novo copy number variant in KCNA1 was identified in a human case of SUDEP. 7, 8 In contrast, Kcnq1 A340E/A340E mice carry a dominant negative missense mutation (A340E) leading to loss-of-function of the Kcnq1 gene, which encodes KCNQ1 (Kv7.1) voltage-gated potassium channel a-subunits. The A340E mutation in mice causes infrequent spontaneous seizures (~0.5/d) and multiple cardiac abnormalities, including AV blocks that occur concomitantly with cortical discharges suggesting that they are brain driven. 9 Although SUDEP has not been documented in Kcnq1 A340E/A340E mice, the homologous A341E mutation in humans causes long QT syndrome type 1 (LQT1), which is strongly associated with sudden death due to ventricular tachyarrhythmias. 9 ,10 KCNQ1 mutations have been identified in patients with epilepsy or a history of seizures suggesting KCNQ1 is also a human epilepsy gene. 11, 12 In this study, we tested the hypothesis that KCNQ channel activation with RTG normalizes neurocardiac function in Kcna1 À/À and Kcnq1 A340E/A340E mice leading to a reduction in seizure susceptibility and cardiac dysfunction. RTG is a potent activator of KCNQ2 (Kv7.2) and KCNQ3 (Kv7.3) voltage-gated potassium channel a-subunits but has no effect on KCNQ1. 13 Our results reveal unexpected effects of genotype on the efficacy and tolerability of KCNQ activation, as well as potentially new cardiovascular roles for KCNQ2-5 channels in the autonomic control of chronotropy. Health Sciences Center-Shreveport. Genotyping was performed as described previously (see Data S1 for details). 
| MATERIALS AND METHODS

| Animals and genotyping
| Flurothyl-induced seizure susceptibility
Flurothyl-induced seizure latencies were measured using the same procedure as described previously (see Data S1 for details). 4 Forty minutes prior to seizure induction, mice (age P29-31) were administered VEH or RTG (10 mgÁkg À1 , ip). Mice were then placed in an air-tight Plexiglas chamber (18.4 9 15.0 9 34.5 cm) and allowed to acclimate for 5 minutes before exposure to the liquid convulsant flurothyl (2,2,2-trifluoroethyl ether; SigmaAldrich, St. Louis, MO, USA).
| Simultaneous electroencephalographyelectrocardiography (EEG-ECG) recordings
Mice (~4 weeks old) were anesthetized with avertin (0.02 mLÁg À1 , ip) and surgically implanted with bilateral silver wire EEG (temporal and frontal) and ECG (thoracic) electrodes (0.005-inch diameter) attached to a microminiature connector for recording in a tethered configuration as done previously (see Data S1 for details). 4 Avertin was prepared by mixing 250 mg 2,2,2-tribromoethanol (SigmaAldrich) with 155 lL 2-methyl-2-butanol (Sigma-Aldrich) dissolved in 19.75 mL double-distilled water heated to 40°C, followed by filter-sterilization prior to use. Simultaneous video and cortical EEG-ECG activity were recorded in freely moving mice using a digital video EEG-ECG monitoring system (Data Sciences International, St. Paul, MN, USA). Mice were monitored by video EEG-ECG over an 8-hour daytime recording period for 3 consecutive days.
Vehicle was administered at the beginning of each 8-hour recording session, followed by RTG 4 hour later. To determine drug effects, mice were used as their own controls by comparing their responses to VEH and drug. EEG-ECG recordings were analyzed offline using Ponemah software (Data Sciences International) to manually identify spontaneous seizures and cardiac events by an observer blinded to genotype as described in detail in the Data S1.
2.6 | Heart rate (HR) and heart rate variability (HRV) analyses
Ponemah software (Data Sciences International) was used to automatically generate RR interval data for the first day of EEG-ECG recording for each animal. The RR intervals were used to calculate the average HR for each minute of recording for the 2 hour immediately following VEH and RTG administration. For HR and HRV analyses, values for each animal were derived by averaging 3 stable 3-minute ECG segments when the mouse was mostly stationary, beginning at 30-minute after administration of either VEH or RTG. HRV was measured in the time domain using the standard deviation of the RR intervals (SDNN) and the root mean square of successive differences (RMSSD) as done previously. 4 All cardiac parameters were measured during the light phase of the day between 10:30 AM and 4:30 PM.
| Quantitative PCR (qPCR) analyses
Following isoflurane euthanasia, brains of mice (age P29-31) were quickly harvested, dissected, and collected. Total RNA was isolated using TRI-Reagent (Zymo Research, Irvine, CA, USA), purified using PureLink RNA Mini Kit (Thermo Fisher, Waltham, MA, USA), and processed for relative qPCR analyses of messenger RNA (mRNA) transcript levels using TaqMan probes (Thermo Fisher), as described in detail in the Data S1. Reactions were normalized to the housekeeping gene hypoxanthine phosphoribosyl-transferase 1 (Hprt1). Relative mRNA expression was calculated as normalized values by use of the 2 ÀDCt formula.
| Statistical analyses
All data are expressed as mean AE standard deviation. mice of both strains exhibited varying degrees of the expected muscle-relaxant behavior, which we termed immobility, which was characterized by a motionless flattened posture with thoracic and abdominal areas resting against the floor of the cage ( Figure 1A ,B). However, RTG-induced immobility was much more pronounced and long lasting in mice from the Kcnq1 strain (C57BL/6) compared to the Kcna1 strain (Tac:N:NIHS-BC), even at lower doses ( Figure 1A ,B). In contrast to the normal sedative-like drug response in WT animals, RTG (5-20 mgÁkg À1 ) never induced immobil-
mice exhibited unexpected behavioral responses to RTG, including full-body jerking and twitching (termed myoclonus) beginning at low doses (5 mgÁkg À1 ), which evolved to include hopping and vocalization at higher doses (10-20 mgÁkg À1 ; Figure 1C ,E,F). Unlike Kcna1 À/À animals, Kcnq1 A340E/A340E mice rarely exhibited myoclonic behavior in response to RTG ( Figure 1D ), and hopping and vocalizing was never observed at any dose (data not shown).
| RTG increases seizure threshold in
Kcnq1 mice, but has no effect in Kcna1 mice
To determine whether RTG decreases seizure susceptibility in Kcna1 and Kcnq1 mice, animals were injected with either VEH or RTG (10 mgÁkg À1 ) followed by exposure to the convulsant flurothyl to induce seizure activity, which manifests as initial myoclonic jerks that progress to generalized tonic-clonic seizure. In this and subsequent experiments, RTG was administered at a dose of 10 mgÁkg À1 (unless otherwise stated) to avoid excessive confounding effects of behavioral toxicity such as the myoclonus, hopping, and vocalizing that occurs at higher doses in Kcna1 À/À mice. Upon flurothyl exposure, VEHinjected Kcna1 À/À mice exhibited latencies to myoclonic jerks and tonic-clonic seizure that were reduced by about 50% compared to their Tac:N:NIHS-BC WT littermates (Figure 2A ,C), similar to previous reports. 4 However, VEH-injected Kcnq1 A340E/A340E mice showed latencies that were not significantly different from their C57BL/6 WT counterparts ( Figure 2B,D) , indicating that the Kcnq1 A340E mutation does not affect seizure threshold despite the occurrence of infrequent spontaneous seizures in this model. 9 When injected with RTG, Kcna1 À/À mice and Tac:N:NIHS-BC WT littermates exhibited latencies that were unchanged compared to VEH, suggesting that a 10 mgÁkg À1 dose of RTG has no effect on seizure susceptibility in this mouse strain (Figure 2A,C To determine whether KCNQ activation normalizes heart function in Kcna1 and Kcnq1 mice, various cardiac measures were analyzed using video EEG-ECG recordings: HR, HRV, and skipped heart beats (ie, AV conduction blocks). At baseline with VEH, mice exhibited straindependent differences in cardiac function. Mice from the Kcna1 strain exhibited faster HR with less HRV than mice from the Kcnq1 strain ( Figure 3A -D and Table 1 ). In response to 10 mgÁkg À1 RTG injection, WT and mutant mice of both strains exhibited trends toward a transient decrease in HR. However, the degree and duration of this HR reduction varied by strain and genotype ( Figure 3A ,B, E,F). Whereas Tac:N:NIHS-BC WT mice from the Kcna1 strain exhibited relatively mild (~15%) and short-lived (~15 minute) HR reductions ( Figure 3E ), C57BL/6 WT mice from the Kcnq1 strain exhibited more profound (~40%) and long-lasting (~30 minute) HR reductions (Figure 3F) . RTG responses differed in mutant mice of both strains: Kcna1 À/À mice exhibited~5% reductions in HR that lasted about 5 minutes ( Figure 3E ) compared to Kcnq1 A340E/A340E mice, which showed HR reductions of 45% that lasted up to~90 minute ( Figure 3F ). To assess RTG-induced modification of autonomic control of the heart, HRV was analyzed at 30-minute postinjection using the following time domain measures: the standard deviation of the beat-to-beat intervals (SDNN), an index of the total autonomic variability; and the root mean square of the successive beat-to-beat differences (RMSSD), an index of parasympathetic tone. Following VEH injection, mice from the Kcnq1 strain exhibited 2-to 4-fold higher SDNN and RMSSD values relative to Kcna1 strain mice, suggesting higher parasympathetic tone at baseline (Table 1) . Mutant mice from both strains exhibited HRV values that were approximately similar to their WT counterparts (Table 1) . However, baseline RMSSD was nearly twice as high in Kcna1 À/À mice compared to their Tac:N:
NIHS-BC WT controls, consistent with a previous study showing elevated HRV measures of parasympathetic tone in these animals. 4 Upon 10 mgÁkg À1 RTG administration, SDNN (t = 3.488, P = .025, paired t test) and RMSSD (t = 3.373, P = .028, paired t test) significantly increased by 4-fold and 8-fold, respectively, in Kcnq1 A340E/A340E mice compared to VEH (Table 1) , suggesting dysregulation of autonomic control of the heart in response to the drug. In contrast, Kcna1 À/À mice showed no change in HRV following RTG injection ( Table 1) . Next we examined whether acute RTG administration affects the frequency of interictal skipped heart beats, which we use as a biomarker of abnormal cardiac function, indicative of potential autonomic dysregulation. Previous studies have shown that Kcna1 À/À mice exhibit an increased incidence of skipped heart beats due to vagally driven AV conduction blocks. 3 Similarly, Kcnq1
A340E/A340E
mice have also been reported to have increased susceptibility to AV blocks in ECG recordings. 9 Acute RTG Figure 4A,B) . However, this dose of RTG induced a dramatic increase in the rate of skipped beats in mice of the Kcnq1 strain, especially Kcnq1 A340E/A340E mice, which exhibited an increase of~200-800 per hour (equivalent to a ≥20-fold increase; t = 2.891, P = .045, paired t test), suggesting drastic augmentation of parasympathetic tone ( Figure 4C,D) .
3.5 | Kcnq2 mRNA levels are increased in
To test whether the observed differential drug effects were associated with strain-or genotype-based differences in the expression of the main molecular targets of RTG, qPCR was performed to measure the mRNA levels of Kcnq2 and Kcnq3 in the hippocampi and cortices of Kcna1 and Kcnq1 mice (n = 5-6/genotype per brain region). Regional qPCR revealed that the levels of Kcnq2 mRNA, but not Kcnq3, were significantly higher in both the hippocampus (F = 4.815, P = .012, 1-way ANOVA) and cortex (F = 4.275, P = .017, 1-way ANOVA) of Kcna1 À/À mice compared to Kcnq1 mice ( Figure 5 ).
| DISCUSSION
In this study, the efficacy of the KCNQ channel opener RTG and its potential for severe adverse behavioral or cardiac effects was profoundly affected by genetic background, suggesting that KCNQ activation may not be an optimal strategy to combat SUDEP. RTG treatment has been used as an effective adjunctive therapy for the management of drug-resistant partial-onset seizures, but its production was recently discontinued due to limited usage and continued decline in patient initiation. However, RTG is simply one drug that targets KCNQ channels and many other KCNQ activators are currently under development for controlling disorders of neuronal hyperexcitability. 17, 18 Another factor in the demise of RTG as a clinical pharmaceutical was likely the occurrence of unwanted side effects in a subset of patients, as is seen for most antiseizure drugs. The most common adverse events associated with RTG in patients include central nervous system effects, increased risk of urinary retention, and altered skin and retinal pigmentation. 19, 20 In rodents, the main side effect of RTG is a transient reduction in locomotor activity described as flat body posture and some muscle relaxation, 16 as was observed in WT and Kcnq1 A340E/A340E mice in this study. We also observed an additional and previously unreported response to KCNQ activation that was specific to mice with the Kcna1 À/À mutation, namely behavioral hyperexcitability that was characterized by myoclonus, hopping, and vocalization. These behaviors may be the rodent correlate of the tremors that occur in 9% of patients at higher doses of RTG (900 mgÁd À1 ). 19 In one case report, a patient overdosed on the KCNQ opener flupirtine, leading to intermittent myoclonus and active and resting tremor of the extremities reminiscent of the behavior seen in Kcna1 À/À mice. 21 Although the EEG recordings in Kcna1 À/À mice showed some abnormal waveforms following RTG administration, these were more consistent with movement artifacts due to hopping rather than increased cortical excitability ( Figure S2 ). The hyperexcitable behavioral response to RTG in Kcna1 À/À mice provides one possible pharmacogenetic explanation for the adverse behavioral effects of RTG in some patients and suggests that future KCNQ activator drugs should be evaluated for potential behavioral hyperexcitability side effects. KCNQ activation also produced novel genotype-and strain-dependent effects on HR suggesting that KCNQ2-5 channels play a role in autonomic control of chronotropy, which varies based on genetic background. Whereas RTG had no significant cardiac effects in Kcna1 mice, Kcnq1 mice exhibited transient HR decreases that were most pronounced in Kcnq1 A340E/A340E mutants, which exhibited a prolonged fall in HR lasting ≥60 minute coupled with 4-to 8-fold increases in HRV. Cardiovascular roles for KCNQ2-5 channels have been described in visceral sensory neurons and the vasculature, but less is known about their potential roles in regulating cardiac function. ganglion (SCG) neurons where they regulate release of noradrenaline (NA) onto the heart. 23 Unlike KCNQ1, KCNQ2-5 channels are not expressed at significant levels in the heart 24 ; however, their potential compensatory expression in the absence of functional KCNQ1 cannot be ruled out. Previously, in a co-culture preparation of rat SCG sympathetic neurons and mouse cardiomyocytes, RTG abolished the increase in cardiomyocyte constriction rate caused by nicotine-induced stimulation of SCG neurons; however, RTG application to cardiomyocytes cultured alone had no effect. 25 These results suggest that RTG induces upregulation of KCNQ2/3-mediated M-current preventing NA release from SCG cells, which could lead to a bradycardic effect due to sympathetic inhibition consistent with our observations. Although RTG has been shown to have broad spectrum antiseizure activity, our results show that its efficacy depends on the mouse strain and testing paradigm in which it is evaluated. RTG normally exhibits potent antiseizure effects, especially when administered prior to seizure induction, in a variety of in vitro and in vivo rodent models of epilepsy. 16, 26 However, to our knowledge, this is the first study to examine the antiseizure efficacy of RTG in the flurothyl seizure model in mice. We found that although RTG could effectively increase flurothyl-induced seizure latency similar to other chemically induced seizure models, this antiseizure effect was limited to mice from the Kcnq1 strain, suggesting an influence of genetic background of the mouse strain. Of interest, a 10 mgÁkg À1 dose of RTG still significantly reduced the occurrence of spontaneous EEG seizures in Kcna1 À/À mice despite having no effect on flurothyl seizure latency. A similar dissociation has been observed in flurothyl-kindled DBA/2J mice. Following exposure to 8 flurothyl-induced seizures, DBA/2J mice exhibit spontaneous seizures without a significant change in flurothyl seizure threshold from preepileptic levels. 27 The generalized running bouncing seizures that are evoked by prolonged flurothyl exposure involve activation of brainstem centers, whereas the spontaneous seizures in Kcna1 À/À mice show evidence of limbic origin. [27] [28] [29] Therefore, RTG could have contrasting effects on flurothyl-induced and spontaneous seizures due to differences in the neuronal networks underlying onset or propagation of the 2 types of seizures. Quantitative PCR analyses revealed high Kcnq2 transcript levels in the hippocampus and cortex of Kcna1 À/À mice that could be partly due to a neuronal homeostatic control response that is the product of the expression and functional complementarity between Kv1.1 and KCNQ2 channels. Kv1.1 and KCNQ2 channels share widespread expression throughout many common brain areas including cortex, hippocampus, thalamus, and cerebellum. 30, 31 cochlear nucleus, which, following deprivation of afferent inputs by removing the cochlea, switch their dominant Kv channel composition from Kv1.1 to KCNQ2 to maintain homeostasis of auditory circuits. 35 The ability of Kv1.1 and KCNQ2 channels to partially compensate for one another is facilitated by their similar electrophysiologic properties, including similar low-voltage activation characteristics and the ability to directly affect action potential threshold according to their different activation kinetics. 35, 36 In patients, gene mutations in either KCNA1 or KCNQ2 lead to similar functional consequences including epilepsy or peripheral nerve hyperexcitability. 8, 37 In addition to potential homeostatic compensation, Kcnq2 transcripts may also be elevated in Kcna1 À/À mice due in part to the genetic background of the mouse strain, since the Kcna1 strain exhibits slightly elevated basal levels of Kcnq2/3 expression. Epilepsy in Kcna1 À/À mice could also play a role, leading to seizure-induced increases in the transcription of Kcnq2, which could alter the effects of RTG in accordance with the target hypothesis of pharmacoresistance, which states that epilepsy-related changes in the properties of drug targets themselves may result in altered drug sensitivity. 38 Because expression changes at the mRNA level do not always correlate with alterations in protein abundance, future studies will be needed to address whether the changes in Kcnq2 mRNA expression correlate with changes in KCNQ2 protein.
In summary, from a clinical perspective, this study demonstrates the principle that treatment strategies in channelopathy may have unexpected outcomes. Our findings show that activation of KCNQ channels does not prevent neurocardiac dysfunction, at least in the mouse models tested. Furthermore, KCNQ activation led to unexpected adverse strain-and genotype-dependent effects in mice that suggest this class of drugs may be contraindicated in patients with KCNA1 or KCNQ1 mutations. The differential effects of KCNQ activation may be partly due to underlying differences in Kcnq2/3 channel expression, which could alter drug target levels. Our findings emphasize the importance of an individual's genomic profile in determining drug responsiveness, toxicity, and sensitivity, providing a clear example of pharmacogenetic interactions in epilepsy that could contribute to pharmacoresistance. Achieving effective therapeutic rebalancing of channel defects will require improved understanding of channel interactions at the circuit and tissue levels.
